MMV supports trials of a new preventive treatment option for pregnant women

MMV, Pfizer and LSHTM collaborate to develop a new combination dose of azithromycin and chloroquine phosphate as Intermittent Preventive Therapy for pregnant women.

23 Apr 2010

Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.

Note: The AZCQ programme has been discontinued. Read more.